Cargando…

Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer

Folate receptor (FR) overexpression occurs in a variety of cancers, including pancreatic cancer. In addition, enhanced macropinocytosis exists in K-Ras mutant pancreatic cancer. Furthermore, the occurrence of intensive desmoplasia causes a hypoxic microenvironment in pancreatic cancer. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yang-Yang, Li, Liang, Liu, Xiu-Jun, Miao, Qing-Fang, Li, Yi, Zhang, Meng-Ran, Zhen, Yong-Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091918/ https://www.ncbi.nlm.nih.gov/pubmed/35582405 http://dx.doi.org/10.1016/j.jpha.2021.07.001

Ejemplares similares

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer
por: Du, Yue, et al.
Publicado: (2016)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways
por: Padavano, Julianna, et al.
Publicado: (2015)

Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice
por: Salaymeh, Yaser, et al.
Publicado: (2020)

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition
por: Hamada, Shin, et al.
Publicado: (2021)

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
por: Hofmann, Irmgard, et al.
Publicado: (2012)

K-RAS Mutant Gene Found in Pancreatic Juice Activated Chromatin From Peri-ampullary Adenocarcinomas
por: Reza, Joseph, et al.
Publicado: (2019)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis
por: Tao, Lian-yuan, et al.
Publicado: (2016)

Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing Mutant ras Gene
por: Ura, Hitoshi, et al.
Publicado: (1994)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

The thiol-sulfoxonium ylide photo-click reaction for bioconjugation
por: Wan, Chuan, et al.
Publicado: (2022)

The Therapeutic Effect of Cytokine-Induced Killer Cells on Pancreatic Cancer Enhanced by Dendritic Cells Pulsed with K-Ras Mutant Peptide
por: Tan, Guang, et al.
Publicado: (2011)

Recyclable Cu(i)/melanin dots for cycloaddition, bioconjugation and cell labelling
por: Sun, Yao, et al.
Publicado: (2016)

Development of Bioorthogonal Reactions and Their Applications in Bioconjugation
por: Zheng, Mengmeng, et al.
Publicado: (2015)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer
por: Yuan, Bo, et al.
Publicado: (2022)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

TOB1 suppresses proliferation in K‐Ras wild‐type pancreatic cancer
por: Bai, Yuru, et al.
Publicado: (2019)

Bioconjugation and stabilisation of biomolecules in biosensors
por: Liébana, Susana, et al.
Publicado: (2016)

Tyrosine bioconjugation – an emergent alternative
por: Szijj, Peter A., et al.
Publicado: (2020)

Tyrosine bioconjugation with hypervalent iodine
por: Declas, Nina, et al.
Publicado: (2022)

Temporal Dissection of K-ras(G12D) Mutant In Vitro and In Vivo Using a Regulatable K-ras(G12D) Mouse Allele
por: Wang, Zuoyun, et al.
Publicado: (2012)

The Importance of Mg(2+)‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
por: Pálfy, Gyula, et al.
Publicado: (2022)

Tetra-fluorinated aromatic azide for highly efficient bioconjugation in living cells
por: Cai, Xuekang, et al.
Publicado: (2018)

Correction: Temporal Dissection of K-ras(G12D) Mutant In Vitro and In Vivo Using a Regulatable K-ras(G12D) Mouse Allele
por: Wang, Zuoyun, et al.
Publicado: (2012)

Identification of K‐ras Oncogene Mutations in the Pure Pancreatic Juice of Patients with Ductal Pancreatic Cancers
por: Watanabe, Hiroyuki, et al.
Publicado: (1993)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Accelerated pharmaceutical protein development with integrated cell free expression, purification, and bioconjugation
por: Richardson, Dominique, et al.
Publicado: (2018)

Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
por: Tokunaga, T, et al.
Publicado: (2000)

Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours
por: Lin, S-R, et al.
Publicado: (2000)

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
por: Cekani, Elona, et al.
Publicado: (2022)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Killer K-Ras
por: Powell, Kendall
Publicado: (2006)

K-RAS Is…Complicated
por: Clark, Geoffrey J.
Publicado: (2023)

Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy
por: Yang, Seong-Bin, et al.
Publicado: (2022)

Bromopyridazinedione-mediated protein and peptide bioconjugation
por: Chudasama, Vijay, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0vrn4ram6dceqbb0nv05v0l1a7